Introduction {#Sec1}
============

Between 20 and 40 % of patients with cancer develop brain metastases of which 2--5 % arise in the brainstem \[[@CR1]--[@CR5]\]. While brainstem metastases represent a small proportion of brain metastases overall, these lesions are challenging in terms of management, and prognosis is traditionally poor. Given the critical functions performed by the brainstem, surgery is not typically utilised, and the preferred treatment is with radiation, either with conventionally fractionated external beam radiotherapy or stereotactic radiosurgery (SRS).

Radiosurgery is an established treatment modality for brain metastases, commonly offered when the metastases are limited in number and size (generally \<3 cm in diameter) \[[@CR6]\]. The highly conformal nature of SRS treatment allows a much higher dose to be delivered to the tumour than can be achieved with conventionally fractionated radiotherapy, without excessive damage to the surrounding normal tissues.

Since the brainstem is considered an eloquent area, where salvage surgical resection in the event of brainstem radionecrosis is not easily achieved, there have been concerns about the safety of SRS in this location. Given this, and the fact that brainstem metastases are relatively infrequent, the use of SRS in the brainstem is relatively under-represented in the literature. Here, we present the clinical outcomes for 44 patients with 48 brainstem metastases treated with SRS with and without whole brain radiotherapy along with investigation of patient and treatment-related factors that could potentially impact outcomes.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Following approval by the institutional research ethics board for the period April 2006 to June 2012, patients who received SRS at University Health Network (Princess Margaret Cancer Centre and Toronto Western Hospital) for brainstem metastases during the above time period were identified from a prospective brain metastases database. The following details were recorded: age, gender, primary tumour histology, number of brainstem lesions, brainstem location, presence of additional non-brainstem brain metastases at time of brainstem SRS, extra-cranial disease control at time of brainstem SRS, use of additional radiotherapy and dose, site and timing of additional brain radiotherapy.

Stereotactic radiosurgery {#Sec4}
-------------------------

All patients were treated using the Gamma Knife® 4C or Perfexion™ radiosurgery unit (Elekta AB, Stockholm, Sweden). Patients were immobilised using a Leskell stereotactic frame. Using the GammaPlan® system (Elekta AB, Stockholm, Sweden), patient MR (gadolinium-enhanced T1-weighted and T2-weighted) and CT images were imported for target and organ-at-risk delineation, and radiosurgery plans were generated. All patients received single fraction SRS. The dose prescriptions were based on volume and generally followed the RTOG guidelines, while limiting dose to the surrounding brainstem to try to keep the maximum dose to 1mm^3^ brainstem less than 15 Gy. It was aimed to keep the conformality index less than 2. The following dosimetric parameters were recorded: target volume, largest extent of target, conformality index, gradient index, minimum target dose, maximum target dose, mean target dose, and prescription isodose.

Patient follow-up {#Sec5}
-----------------

All patients were reviewed prior to SRS in a dedicated multi-disciplinary brain metastases clinic. Following SRS, all patients were followed up in the same clinic at 3-month intervals, with serial brain MRI and neurological assessment. Changes in target lesions were defined according to RECIST criteria \[[@CR7]\], as a number of these brainstem metastases did not all meet the minimum diameter requirement of 10 mm described in the Response Assessment in Neuro-Oncology criteria for brain metastases \[[@CR8]\].

Statistics {#Sec6}
----------

All statistical analysis was completed using SPSS version 21 (IBM, USA), and *p* \< 0.05 was considered statistically significant. The Kaplan-Meier method was used to calculate survival outcomes. Overall survival was defined as the date of Gamma Knife treatment to date of death or censored at last follow-up. For overall survival and distant brain failure, calculations were on a per patient basis (i.e. patients with more than one brainstem lesion were only considered once in the analysis), and where patients had brainstem lesions treated sequentially, overall survival was considered from the date of the first brainstem radiosurgery treatment. Local failure was defined on an individual lesion basis as the date of Gamma Knife treatment to the date of first reported radiological progression. Lesions that progressed on imaging and/or caused new neurologic symptoms but which resolved without any further anti-cancer treatment were considered radionecrosis rather than local progression. Distant brain failure was defined as the development of new metastases in the brain but not within the brainstem.

Univariate and multivariable Cox regression were used to investigate factors predictive of overall survival. For univariate analysis, patient age, gender, primary tumour histology (breast, non-small cell lung vs. other), the use of additional brain radiotherapy, the presence of synchronous non-brainstem brain metastases at the time of brainstem SRS, extra-cranial disease control, local failure and distant brain failure were evaluated. Any covariates with a *p* value of 0.1 or less were intended for inclusion in the multivariable model for overall survival. Factors potentially predictive of local control or radionecrosis were not investigated in a univariate or multivariable context given the low number of events and small sample size.

Results {#Sec7}
=======

Patients {#Sec8}
--------

In total, 44 patients received SRS for 48 brainstem lesions, including 3 patients in whom two brainstem lesions were treated synchronously and one patient who received two sequential SRS treatments to the same brainstem metastasis. Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. Median follow-up was 16.1 months (range 0--54.0). Median age at SRS was 58 years (range 32--76) and 36 % of patients were male (*n* = 16). All patients had KPS \> 60 at the time of brainstem SRS. The most frequent primary tumour histologies were non-small cell lung cancer (*n* = 14, 32 %) and breast cancer (*n* = 12, 27 %). Brainstem metastases represented the only intra-cranial metastasis in 17 patients (39 %), while 11 patients (25 %) had one other brain lesion at the time of brainstem SRS, and the remainder had two or more additional lesions (up to a maximum of 9 non-brainstem brain metastases). The majority (*n* = 33, 75 %) of patients received whole brain radiotherapy (WBRT) during their course of care: 23 patients (52 %) had received WBRT prior to SRS to the brainstem metastases, 6 patients (13.6 %) received WBRT concurrently with brainstem SRS (defined as within 4 weeks of SRS) and 4 patients (9.0 %) received WBRT after SRS. A further two patients received base of skull radiotherapy prior to brainstem SRS and one additional patient received radiotherapy for a temporal bone lesion prior to brainstem SRS. In 8 patients, a second course of WBRT was also delivered at further progression, and in 1 patient, who received base of skull radiotherapy prior to brainstem SRS, WBRT was delivered at further progression.Table 1Baseline characteristics (no. patients: 44, no. lesions: 48)Factor*n*%AgeMedian 58Range 32--76Gender Male1636.4 Female2864.6Primary tumour: Breast1227.3 Non-small cell lung cancer1431.8 Gynaecological613.6 Melanoma36.8 Renal24.5 Colorectal24.5 Other511.4Site of brainstem metastasis Midbrain510.4 Pons2960.4 Medulla612.5 Pons-midbrain36.3 Pons-medulla510.4Number of brainstem lesions 14090.9 2 treated synchronously36.8 2 treated sequentially12.3Additional non-brainstem brain metastases at time of brainstem SRS 01738.6 11227.3 224.5 3715.9 \>3613.6Other brain radiotherapy None818.2 WBRT prior to SRS2352.3 Other brain RT prior to SRS^a^36.8 WBRT concurrent with SRS613.6 WBRT after SRS49.1 Re-WBRT after SRS818.2Extra-cranial disease status at time of SRS Controlled2045.5 Uncontrolled1840.9 Unknown613.6*SRS* stereotactic radiosurgery, *WBRT* whole brain radiotherapy^a^Two patients have base of skull radiotherapy and one had IMRT for a temporal bone lesion

Dosimetry {#Sec9}
---------

Dosimetric factors are summarised in Table [2](#Tab2){ref-type="table"}. The most commonly prescribed marginal dose was 15 Gy (*n* = 38 lesions, 79.2 %), most often prescribed to the 50 % isodose (median prescription isodose: 50 %, range 39--80 %), resulting in a median mean dose of 20.8 Gy (range 13.9--35.0). The median brainstem metastasis volume was 1.33 cc (range 0.04--12.17 cc). Plans were highly conformal with steep dose gradients (Table [2](#Tab2){ref-type="table"}), thus limiting the dose to the surrounding normal tissues. Of the 33 patients who received WBRT, 18 (54.5 %) received 20 Gy in 5 fractions, 14 (31.8 %) received 30 Gy in 10 fractions and 1 (2.3 %) received 25 Gy in 10 fractions. Both of the patients who received base of skull radiotherapy prior to SRS received 20 Gy in 5 fractions and the one patient who had received radiotherapy for a temporal bone lesion received 55 Gy in 50 fractions in a BID schedule resulting in a maximum brainstem dose of 22 Gy. Of the 8 patients who received 2 courses of WBRT, patients largely received 20 Gy in 5 fractions for their first course of WBRT, with just 2 patients who received 30 Gy in 10 fractions. Half of patients received 25 Gy in 10 fractions for their second course of WBRT, although 20 Gy in 10 fractions and 15 Gy in 5 fractions were also delivered as the second course. The full summary is provided in Online Resource [1](#MOESM1){ref-type="media"}. One patient who had received skull base radiotherapy, 20 Gy in 5 fractions, prior to brainstem SRS also went on to receive WBRT following brainstem SRS at a dose of 25 Gy in 10 fractions.Table 2Dosimetric parametersParameterMedianRangeTarget volume (cc)1.330.04--12.17Largest extent of target (mm)16.954.70--37.00Prescribed dose (Gy)*n*% 15 Gy3879.2 12 Gy^a^612.5 10 Gy12.1 14 Gy12.1 18 Gy12.1 22 Gy12.1Prescription isodose (%)5039--80Conformality index1.251.04--2.85Gradient index2.902.29--4.44Target minimum dose (Gy)12.907.94--19.56Target maximum dose (Gy)29.9418.76--48.98Target mean dose (Gy)20.8313.89--34.96^a^This dose was used for the one case of SRS re-treatment of a brainstem metastasis

Survival and brain response {#Sec10}
---------------------------

Median overall survival was 23.6 weeks (95 % CI: 16.2 to 31.0 weeks) with 1- and 2-year overall survival of 33.4 and 15.6 %, respectively (Fig. [1](#Fig1){ref-type="fig"}a). There were no deaths within 30 days of brainstem SRS.Fig. 1**a** Overall survival. **b** Freedom from local failure. **c** Freedom from distant brain failure

Overall, 27 brainstem metastases (in 25 patients) were evaluable on follow-up MRI imaging. Response was unknown for the remaining 21 lesions (19 patients), due to death prior to the 3-month post-SRS scan (*n* = 9) or loss to imaging follow-up. Of the 27 lesions with imaging follow-up, there were 2 complete responses, 12 partial responses and 9 cases of stable disease. Local failure was recorded on 4 occasions in 3 patients, including the 1 patient who was treated with salvage radiosurgery to the same brainstem metastasis. The 6-month, 1- and 2-year freedom from local failure was 84.6, 76.9 and 61.5 %, respectively (Fig. [1](#Fig1){ref-type="fig"}b). Of the 3 patients who developed local failure, two had a diagnosis of non-small cell lung cancer and one had breast cancer. All 3 patients had received WBRT prior to brainstem SRS. In all 4 cases of local failure, the metastases were relatively small (volumes: 0.4--3.57 cc, maximum diameters: 10.5--21 mm). In all 3 patients with local failure, the marginal prescription dose was 15 Gy for the first brainstem SRS treatment. For the one patient (with a diagnosis of breast cancer) who received a second SRS treatment for local progression of the brainstem metastasis, a marginal dose of 12 Gy was prescribed for re-treatment. Following the brainstem SRS retreatment, there was radiological evidence of progression of the retreated brainstem lesion. This was accompanied by progression of additional non-brainstem brain metastases. Progression of all intra-cranial lesions continued on serial imaging, and so appearances were in keeping with disease progression and not brainstem radionecrosis. Thus, despite two SRS treatments to the same area (and previous WBRT), this patient did not develop radionecrosis or any other significant treatment-related toxicity.

Distant brain progression was reported in 14 patients of whom 8 (57.1 %) had received prior WBRT. Of the 29 patients who received WBRT prior to or concurrent with brainstem SRS, 8 (27.6 %) developed distant brain progression compared to 6 of the 12 patients (50 %) who received SRS alone. Within the whole group, median time to distant brain progression was 56.1 weeks with 6-month, 1- and 2-year freedom from distant brain progression of 54.8, 54.8 and 25.1 %, respectively (Fig. [1](#Fig1){ref-type="fig"}c).

Treatment-related toxicity {#Sec11}
--------------------------

Radionecrosis was observed in 4 patients (9 %), 2 of whom were symptomatic (4.5 % of all patients). Of the two symptomatic patients, one developed quadriparesis 6 months after SRS and improved clinically and on imaging with dexamethasone. The other symptomatic patient developed right leg pain, dizziness and speech difficulties 7 months after SRS. The patient had partial improvement with dexamethasone and subsequently received hyperbaric oxygen, which stabilised symptoms and improved the radiologically evident edema. The two asymptomatic patients developed radionecrosis 6 and 8 months following SRS. All 4 patients were prescribed marginal prescription doses of 15 Gy to relatively small brainstem lesions (target volumes: 1.26 cc to 3.18 cc, maximum dimensions: 19.0 to 22.4 mm) and all had received prior whole brain radiotherapy (20 Gy in 5 fractions in 2 patients and 30 Gy in 10 fractions in 2 patients). Other than these cases of radionecrosis, there were no other grade 3 or greater toxicities.

Factors predictive of survival {#Sec12}
------------------------------

On univariate analysis, no factors were identified that had a statistically significant impact on overall survival (Table [3](#Tab3){ref-type="table"}). There was a trend towards better overall survival in patients who did not receive external beam brain radiotherapy (*p* = 0.078), which included WBRT (*n* = 33), base of skull (*n* = 2) or temporal bone (*n* = 1) radiotherapy (Fig. [2](#Fig2){ref-type="fig"}). Neither local failure, nor distant brain failure, had a statistically significant impact on overall survival. As above, given the small sample size and low number of events, statistical exploration for factors predictive of local control or toxicity was not performed.Table 3Univariate analysis for overall survival (hazard ratio and 95 % confidence interval only reported where *p* \< 0.1)Factor*p* valueHazard ratio95 % confidence intervalAge0.463Gender0.745Additional external beam brain radiotherapy (received vs. not received)^a^0.0783.8040.861--16.806Synchronous non-brainstem brain metastases at time of brainstem SRS (present vs. absent)0.250Histology of primary lesion0.365Extra-cranial disease control at time of brainstem SRS0.609Local brain failure (yes vs. no)0.187Distant brain failure (yes vs. no)0.592^a^Factor entered into multivariate model Fig. 2Patients receiving SRS for brainstem metastases, with or without additional external beam brain radiotherapy (*blue line*: no other brain radiotherapy, *green line*: other brain radiotherapy; *p* = 0.078)

Discussion {#Sec13}
==========

Despite the precision and dose conformality of radiosurgery, there have been concerns about the safety of using SRS for the treatment of brainstem metastases. Our retrospective study supports that SRS for brainstem metastases results in good local control (76.9 % at 1 year) and is well tolerated by the majority of patients with symptomatic radionecrosis in only 2 patients (4.5 %). This is one of the largest series describing outcomes following WBRT in combination with brainstem SRS (*n* = 33), and to our knowledge, this is the largest reported experience of patients treated with a second course of WBRT at progression after brainstem SRS (*n* = 8). Our experience, along with 2 other studies involving a total of only 6 patients, demonstrates the safe delivery of 2 courses of WBRT with SRS to the brainstem without significant toxicity \[[@CR9], [@CR10]\].

In our review of the literature, a further 20 studies have specifically examined SRS for brainstem metastases using Gamma Knife or linear accelerator-based SRS (Table [4](#Tab4){ref-type="table"}), \[[@CR11]--[@CR23], [@CR10], [@CR24], [@CR9], [@CR25]--[@CR28]\]. Although patient numbers tend to be small, collectively, these studies report outcomes for over 1000 patients and over 1100 brainstem metastases treated with SRS. Based on these publications, we can generally conclude that high rates of local control can be achieved with infrequent serious toxicity in this patient population with relatively short overall survival. Median overall survival was 5.4 months in this current study, towards the lower end of that reported in other series with median survival ranging from 4.9 to 12 months (Table [4](#Tab4){ref-type="table"}), perhaps reflecting the fact that most of the patients (75 %) in this series received brainstem SRS as a salvage treatment following previous WBRT, rather than as an upfront treatment option. It has been observed that brainstem metastases, more than other intra-cranial locations, have a negative impact on overall survival \[[@CR29], [@CR30]\], with median survivals of 4.4 and 6.5 months with and without brainstem metastases reported in one matched analysis \[[@CR30]\]. Although the brainstem location appears to impact overall survival, neither local nor distant brain failure significantly impacted overall survival in our study.Table 4Studies investigating SRS for brainstem metastasesStudyModalityNumber of patientsNumber of brainstem metastasesFU (months)Volume of metastases (cc)Marginal dose (Gy)Local control (%)OS (months)WBRT (%; dosimetric details where available)ToxicityHuang et al., 1999^10^GK2627Median 9.5Mean 2.0Median 16.0Crude 95 %Median 992.3 % (median dose 30 Gy, range 23.4--44 Gy), 5 received extra plus 10 Gy at time of SRS as \>3 months from WBRT4 cases of mild and transient toxicity, 3 cases of seizuresShuto et al., 2003^11^GK2531Mean 5.2Mean 2.1Mean 13.0Crude 77.4 %Median 4.928.0 % (range 30--45 Gy)2 cases of brain injuryFuentes et al. , 2006^12^GK28NRMedian 12.5Mean 2.1Mean 16.6 if previous WBRT, Mean 20 Gy if no previous WBRTCrude 92 %Median 1221.4 %NoneHussain et al. 2007^13^GK2225Median 26.6Median 0.9Median 16Crude 100 %Median 8.513.6 %1 episode of persistent hemiparesisYen et al., 2007^14^GK5353Mean 9.8Mean 2.8Mean 17.6Median 1139.6 %NoneKased et al., 2008^15^GK4244Mean 6.9Median 0.26Median 161 year 77 %Median 957.1 %4 episodes of complications including 2 episodes of radionecrosisLorenzoni et al., 2009^24^GK2527Mean 10.5Mean 0.6Mean 20 Gy overall Mean 18.4 if previous brain RT, Mean 21.3 if no previous RT2 years 89 %Median 11.168.0 %NoneSamblas et al., 2009^16^Linac2830NRMean 1.86Mean 11.1Crude 95 %Mean 16.896.4 % (30 Gy in 10 fractions)NoneKoyfman et al., 2010^17^GK4343Mean 5.3Mean 0.37Median 15.01 year 85 %Median 5.879.1 % (median dose 35 Gy)No grade 3+ toxicities, 3 episodes of grade 1 or 2 complications, 2 cases of radionecrosis on imagingHatiboglu et al., 2011^26^Linac6060Median 12.8Median 1.0Median 15Crude 76 %Median 4.025 %12 episodes of complications (all grades), 2 majorKelly et al., 2011^18^Linac24NRMedian 6.6Median 0.2Median 131 year 78.6 %Median 5.395.8 % (median dose 35 Gy, range 30--40 Gy)2 episodes of grade 3 toxicityValery et al., 2011^25^Linac3043Mean 10.2Mean 2.8Mean 13.41 year 79 %Median 1026.7 %No grade 3+ toxicity, 4 episodes of grade 1 or 2 complicationsYoo et al., 2011^19^GK3232Mean 12Mean 1.5Mean 15.9Crude 87.5 %Mean 7.7NR1 episode of haemorrhageKawabe et al., 2012^20^GK200222Median 5.8Median 0.2Median 182 year: 81.8 %Median 66.5 %1 episodes of severe oedema, 6 asymptomatic cases of oedemaLin et al., 2012^21^Linac4548-Median 0.40Median 141 year 88 %Median 11.646.7 % (median dose 37.5 Gy)2 episodes of toxicity, rate 4.7 % at 2 years, 1 episode of symptomatic radionecrosisJung et al., 2013^22^GK3232Median 12.5Median 0.71Median 13Crude 87.5 %Median 5.253.1 % (30 Gy in 10 fractions)NoneSengoz et al., 2013^9^GK4446NRMedian 0.6Median 16Crude 96 %Median 865.9 %2 episodes of asymptomatic peri-tumoral change on MRIKilburn et al., 2014^23^GK4452Median 6Median 0.134Median 181 year 74 %Median 656.8 %4 episodes of toxicity (3 grade 3), including 2 cases of suspected radionecrosisTrifiletti et al., 2015GK161189Median 5.5Median 0.4Median 181 year 84.9 %Median 5.551.6 %3 episodes of severe toxicity including 1 possible episode of radionecrosis causing 2 severe toxicitiesVoong et al., 2015^8^GK7477Median 5.5Median 0.13Median 161 year 85 %Median 8.558.1 %6 cases, including 2 cases of radionecrosisCurrent studyGK4448Median 16.1Median 1.33Median 151 year 79 %Median 5.675.0 % (median 20 Gy, range 20--30 Gy)4 cases of which 2 symptomatic*NR* not reported, *WBRT* whole brain radiotherapy

There have been mixed reports about the impact of marginal dose on outcomes including overall survival and local control. Lorenzoni et al. identified that doses above 18 Gy predicted improved overall survival, and Trifiletti et al. and Kased et al. both demonstrated that doses of 16 Gy and above resulted in improved local control \[[@CR16], [@CR25], [@CR28]\]. Other studies did not find marginal dose as an important predictor for local control or overall survival in patients treated with SRS for brainstem metastases \[[@CR18], [@CR19], [@CR21], [@CR24], [@CR26]\]. Despite the majority of our patients receiving a lower marginal prescription dose of 15 Gy compared with other studies, local control was 78.6 % at 1 year in our series compared with at least 74 to 88 % in other series. (Table [4](#Tab4){ref-type="table"}) and our overall survival was comparable to other studies. Relative to other studies that reported WBRT doses up to 45 Gy combined with SRS to the brainstem, the WBRT doses employed in our study were lower and hypofractionated \[[@CR11], [@CR12], [@CR17]--[@CR19], [@CR22], [@CR23]\], but outcomes were similar to published series. The impact of WBRT dose on local control and toxicity when used in conjunction with brainstem SRS has not been investigated or reported previously.

In this current study, brainstem SRS was well tolerated by most patients with 4 cases of radionecrosis as the only treatment-related toxicities, of which only 2 patients were symptomatic. In existing studies, serious toxicities have also been uncommon, consistently involving less than 10 % of patients (Table [4](#Tab4){ref-type="table"}). Kilburn et al. observed that larger treatment volumes were predictive of toxicity in a series of 44 patients in whom 4 patients developed toxicity (one grade 2, three grade 3), including 2 patients who developed symptomatic radionecrosis (4.4 %) \[[@CR24]\]. Our rate of symptomatic radionecrosis was similar at 4.5 %, but the target volumes in the cases that developed radionecrosis were small.

Due to the retrospective nature of this study, there are limitations with the data presented. Firstly, a relatively high proportion of patients were not evaluable for imaging response to brainstem SRS with about half of patients, who died prior to imaging and the other half who did not complete their 3-month post-treatment MRI. The large number lost to follow-up may reflect a combination of factors including the clinical state of these patients with advanced disease who may have been too unwell to attend for further imaging and the long distances patients have needed to travel for follow-up at this large tertiary cancer centre that received referrals from both nearby and remote regions. In addition, due to the retrospective nature of this study, we had incomplete data regarding the details of the presenting symptoms, consistent evaluation in any change of symptoms or dexamethasone use. Therefore, these variables were not included in any statistical analyses.

Despite the large collective number of patients now reported to have received SRS for brainstem metastases, as with this current series, individual studies tend to contain small numbers of patients, limiting the ability to identify factors predictive of local control or overall survival \[[@CR19], [@CR24], [@CR26]\]. Even where statistically significant observations are made, one should exercise caution in the interpretation due to the small sample sizes relative to the number of predictive variables investigated. In this current study, trends were observed towards improved overall survival with the absence of additional fractionated brain radiotherapy and the absence of synchronous non-brainstem brain metastases at the time of SRS. In terms of the use of whole brain radiotherapy, Lorenzoni et al. and Jung et al. similarly found that the absence of whole brain radiotherapy was a significant predictor of improved survival \[[@CR23], [@CR25]\]. In both of these studies, like our study, the majority of patients received SRS as salvage treatment following initial whole brain radiotherapy. As such, these patients were likely later in their course of disease and therefore had an expected shorter survival following SRS than patients who had not received prior brain radiotherapy.

Conclusion {#Sec14}
==========

This retrospective series of patients treated with SRS for brainstem metastases, largely in combination with at least one course of whole brain radiotherapy, demonstrates that this treatment approach is safe and results in good local control. Distant brain failure was lower in patients who received whole brain radiotherapy as part of initial brain metastasis treatment, as demonstrated in prior studies. In this cohort, no variables significantly impacted overall survival, including intracranial control.
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